Methoxyflurane - Penthrox — Competitive Intelligence Brief

Methoxyflurane - Penthrox (Methoxyflurane - Penthrox) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Volatile halogenated anesthetic. Area: Acute Pain Management.

phase 3 Volatile halogenated anesthetic GABA receptors, NMDA receptors Acute Pain Management Small molecule

Target snapshot

Methoxyflurane - Penthrox (Methoxyflurane - Penthrox) — St. Paul's Hospital, Canada. Methoxyflurane is a volatile halogenated anesthetic that provides rapid analgesia and sedation through central nervous system depression.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Methoxyflurane - Penthrox TARGET	Methoxyflurane - Penthrox	St. Paul's Hospital, Canada	phase 3	Volatile halogenated anesthetic	GABA receptors, NMDA receptors
Methoxyflurane, MEOF	Methoxyflurane, MEOF	Sunnybrook Health Sciences Centre	marketed	Volatile halogenated ether anesthetic	GABA receptors, NMDA receptors
Sevoflurane+Nitrous oxide	Sevoflurane+Nitrous oxide	Huazhong University of Science and Technology	marketed	General anesthetic (volatile anesthetic + inhalational anesthetic)	GABA receptors, NMDA receptors
Sevoflurane Inhalational Induction and Maintenance	Sevoflurane Inhalational Induction and Maintenance	Abbott	marketed	Volatile anesthetic agent	GABA receptors, NMDA receptors, potassium channels
Desflurane Inhalant Product	Desflurane Inhalant Product	Sichuan Provincial People's Hospital	marketed	Volatile inhalational anesthetic	GABA receptors, NMDA receptors, potassium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Volatile halogenated anesthetic class)

1. St. Paul's Hospital, Canada · 1 drug in this class